Objective: To examine the prevalence and predictors of potentially inappropriate anticholinergic medication use in older adults with @entity303 . Design: A cross-sectional study. Setting: United States, 2009-2010. @entity1 : Medical Expenditure Panel Survey household component @entity1 aged 65 years or older identified as having @entity303 and using potentially inappropriate anticholinergic medication. Main outcome measures: Prevalence and predictors of potentially inappropriate anticholinergic medication use as per the updated 2012 American Geriatrics Society Beers criteria. Results: A total of 3.78 million older adult @entity1 (95% confidence interval [CI] 3.17 million to 4.38 million) were identified as having @entity303 , for an overall prevalence of 4.81%. Of those @entity1 , an estimated 1.02 million (95% CI 0.70 million to 1.30 million) were reported to use potentially inappropriate anticholinergic medications, for an overall prevalence of 26.95% (95% CI 20.10% to 33.79%). The most frequently prescribed drugs were @entity11440 , @entity2180 , @entity903 , @entity2181 , @entity4489 , and @entity4829 . Multivariable logistic analysis revealed that those @entity1 with the need characteristics of self-reported @entity148 , @entity1316 , and "fair/poor" general health status had increased odds of potentially inappropriate anticholinergic use, while @entity1 with the predisposing characteristic of being aged 75-84 years had decreased odds of potentially inappropriate anticholinergic use. Conclusion: More than one in four older adults with @entity303 were found to use potentially inappropriate anticholinergics. Given the adverse cognitive effects of these medications, there is a strong need to monitor and optimize their use in older adult @entity1 with @entity303 .

Potentially inappropriate anticholinergic medication use in older adults with XXXX .

@entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'Participants'] @entity4489 :: ('MESH:D011398', 'Chemical') :: ['promethazine'] @entity2181 :: ('MESH:C099041', 'Chemical') :: ['tolterodine'] @entity4829 :: ('MESH:C004704', 'Chemical') :: ['cyclobenzaprine'] @entity303 :: ('MESH:D003704', 'Disease') :: ['dementia'] @entity903 :: ('MESH:D017374', 'Chemical') :: ['paroxetine'] @entity1316 :: ('MESH:D019964', 'Disease') :: ['mood disorders'] @entity148 :: ('MESH:D001008', 'Disease') :: ['anxiety'] @entity2180 :: ('MESH:C441209', 'Chemical') :: ['solifenacin'] @entity11440 :: ('MESH:C005419', 'Chemical') :: ['oxybutynin']
@entity303 :: (MESH:D003704,Disease) :: ['dementia']
